The National Health Insurance Authority (NHIA) has announced an increase in the National Health Insurance Scheme (NHIS) medicines list and service tariffs.
According to the Authority, “Service tariffs across the board have been increased by 10%.”
In a statement on Wednesday, February 1, 2023, the authority indicated a surge in medicinal products as well as medical services due to the increase in Active Pharmaceutical Ingredients (APIs).
This means patients and holders of the NHIS card would have to pay more for medicines and services at the various NHIS-accredited facilities. Thus, the review tariffs take effect Wednesday, 1 February.
“Framework medicines have been increased by 50% plus an additional 30% marginal increase by the NHIA, Non-Framework medicines have been reviewed upwards by 20%,” the NHIA revealed in a statement signed by its Corporate Affairs Directorate.
Meanwhile “artemether injection 80mg/ml and levofloxacin infusion 500mg/ml have been added to the NHIA medicines list and will now be reimbursed by the Scheme.”
As a result, framework medicines will be affected with a 50% increase in addition to 30% marginal surge by NHIA.
The NHIA urged the general public and all service providers “to take note of these adjustments which have been effected to correspond to the observed increase in prices of most Active Pharmaceutical Ingredients (APIs).”
READ THE FULL STATEMENT
